News from nektar therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 25, 2015, 09:26 ET

Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain

 Nektar Therapeutics (NASDAQ: NKTR) today announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of...

Feb 24, 2015, 16:10 ET

Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2014. Cash and...

Feb 17, 2015, 16:15 ET

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2014 on Tuesday, February...

Feb 11, 2015, 09:11 ET

Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A

Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today presented additional efficacy and safety data from the...

Jan 06, 2015, 08:30 ET

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

 Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 33rd...

Dec 11, 2014, 18:00 ET

Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer

Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102)...

Dec 09, 2014, 08:00 ET

MOVENTIG® Approved In The European Union For Opioid-Induced Constipation

 Nektar Therapeutics (NASDAQ:NKTR) reported partner AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted Marketing...

Nov 20, 2014, 09:00 ET

Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model

Nektar Therapeutics (NASDAQ: NKTR) today announced results of a study investigating the preclinical anti-tumor activity and tolerability of...

Nov 06, 2014, 16:10 ET

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2014. Cash and investments...

Oct 30, 2014, 08:30 ET

Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2014 on Thursday, November 6,...

Sep 26, 2014, 07:30 ET

Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the Committee for Medicinal Products for Human Use...

Sep 19, 2014, 09:00 ET

Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting

 Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the...

Sep 16, 2014, 12:32 ET

FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA)...

Aug 21, 2014, 15:33 ET

Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients

Nektar Therapeutics (NASDAQ: NKTR) reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of...

Jul 31, 2014, 16:10 ET

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014. Cash and investments in...

Jul 22, 2014, 18:46 ET

Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2014 on Thursday, July 31, 2014,...

Jun 19, 2014, 15:29 ET

Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients

Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published...

Jun 12, 2014, 16:15 ET

US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA)...

Jun 11, 2014, 07:05 ET

Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists

Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, today announced that NASDAQ has...

Jun 01, 2014, 09:00 ET

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting

 Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which...